Last Updated: November 16, 2026

PEGULICIANINE ACETATE - Generic Drug Details

« Back to Dashboard


What are the generic sources for pegulicianine acetate and what is the scope of patent protection?

Pegulicianine acetate is the generic ingredient in one branded drug marketed by Lumicell and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for PEGULICIANINE ACETATE
International Patents:23
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:PEGULICIANINE ACETATE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PEGULICIANINE ACETATE
Generic Entry Date for PEGULICIANINE ACETATE*:
Constraining patent/regulatory exclusivity:
Dosage:

POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for PEGULICIANINE ACETATE

US Patents and Regulatory Information for PEGULICIANINE ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511-001 Apr 17, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511-001 Apr 17, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511-001 Apr 17, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511-001 Apr 17, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Lumicell LUMISIGHT pegulicianine acetate POWDER;INTRAVENOUS 214511-001 Apr 17, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for PEGULICIANINE ACETATE

Country Patent Number Title Estimated Expiration
Australia 2011336660 Methods and systems for spatially identifying abnormal cells ⤷  Start Trial
Australia 2016277654 METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS ⤷  Start Trial
Canada 2824724 PROCEDES ET SYSTEMES DESTINES A IDENTIFIER SPATIALEMENT DES CELLULES ANORMALES (METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS) ⤷  Start Trial
Canada 3080998 PROCEDES ET SYSTEMES DESTINES A IDENTIFIER SPATIALEMENT DES CELLULES ANORMALES (METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS) ⤷  Start Trial
European Patent Office 2435096 PROCÉDÉS ET SYSTÈMES DESTINÉS À IDENTIFIER DE MANIÈRE SPATIALE DES CELLULES ANORMALES (METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Pegulicianine Acetate Market Dynamics and Financial Trajectory

Last updated: September 3, 2026

Pegulicianine acetate, commercialized in the United States as Lumisight, is an FDA-approved fluorescent imaging agent used with the Lumicell Direct Visualization System during breast-conserving surgery. Its commercial opportunity is concentrated in intraoperative margin assessment for breast cancer rather than systemic oncology treatment.

The product has a differentiated regulatory position, but its financial trajectory depends on adoption by breast surgeons, hospital capital-equipment purchasing, reimbursement, procedure-level economics, and clinical evidence showing reduced re-excision rates. Lumicell is privately held and has not publicly disclosed product revenue, pricing, operating margins, or a detailed launch forecast. Public data support a commercial ramp thesis, but not a precise revenue estimate.

What is pegulicianine acetate and how is it used?

Pegulicianine is a fluorescent imaging agent that is administered intravenously before breast-conserving surgery. The agent is designed to accumulate in tumor-associated tissue and produce fluorescence when activated in the tumor microenvironment. The Lumicell Direct Visualization System detects the fluorescence in tissue surrounding the surgical cavity.

The FDA indication covers adult women with breast cancer undergoing lumpectomy as an adjunct to identify cancerous tissue within the breast-conserving surgery cavity. It does not replace standard pathology and is not a standalone diagnostic test. [1]

Product attribute Publicly reported position
Commercial product Lumisight
Active agent Pegulicianine
Salt designation Pegulicianine acetate
Sponsor Lumicell, Inc.
Delivery Intravenous injection
Use Intraoperative visualization during breast-conserving surgery
Companion technology Lumicell Direct Visualization System
Regulatory pathway FDA drug-device combination product
Therapeutic category Surgical imaging and margin assessment
Primary commercial market U.S. breast-conserving surgery

The FDA prescribing information identifies a recommended dose of 1 mg/kg administered intravenously before surgery, with imaging performed during the surgical procedure. The product carries warnings related to hypersensitivity reactions and false-positive or false-negative fluorescence findings. [1]

When did Lumisight receive FDA approval?

The FDA approved Lumisight and the Lumicell Direct Visualization System in 2024. The approval created a commercial pathway for an integrated drug-device platform rather than a conventional pharmaceutical launch. [2]

The approval is strategically important because the drug and imaging system are operationally linked. Hospitals must evaluate the recurring injectable product and the associated visualization equipment as a combined workflow.

FDA regulatory status

Regulatory issue Status
FDA approval Approved in 2024
Indication Adjunctive visualization of cancerous tissue during breast-conserving surgery
Product type Fluorescent imaging agent
Device dependency Yes
Replacement for histopathology No
Approved use in metastatic disease No
Approved use across all solid tumors No
Approved use in mastectomy No, based on the labeled breast-conserving-surgery indication

The label limits the near-term addressable market to procedures in which the surgeon creates a breast-conserving surgery cavity and can use intraoperative imaging to assess residual tissue. Expansion into other cancers or procedures would require additional clinical and regulatory work.

How large is the pegulicianine acetate market opportunity?

The commercial market is tied to annual breast-conserving surgery volume, not the total breast cancer population. The relevant addressable population includes patients who undergo lumpectomy and whose treating institutions can support the required imaging workflow.

Market penetration will be determined by five factors:

  1. The number of breast-conserving procedures performed annually.
  2. The percentage of hospitals with access to the Lumicell visualization system.
  3. Surgeon confidence in fluorescence results.
  4. The effect on positive-margin and re-excision rates.
  5. Hospital and payer willingness to absorb the combined drug, device, staffing, and operating-room costs.

The product has a focused market but a potentially repeatable procedure-based revenue model. Each treated case can generate recurring drug revenue after the hospital has adopted the visualization system. The installed device base can therefore act as a commercial multiplier for future Lumisight sales.

Market expansion potential

The most credible expansion routes are:

  • Increased penetration in U.S. breast-conserving surgery.
  • Use in additional breast cancer subtypes or surgical settings.
  • Expansion into other solid tumors where tumor-associated protease activity can produce useful signal.
  • Additional imaging applications supported by new clinical trials.
  • International regulatory approvals.
  • Partnerships with surgical equipment companies or oncology-focused pharmaceutical companies.

Expansion beyond breast-conserving surgery would materially increase the opportunity but should not be included in a base-case valuation until supported by regulatory approvals and clinical data.

What drives the financial trajectory for Lumisight?

Lumisight’s financial trajectory should be modeled as an adoption-led medical technology launch rather than a conventional high-volume prescription drug launch.

A simplified revenue framework is:

Revenue = eligible procedures × adoption rate × cases per account × net price per case

The most important operating variables are account acquisition, utilization per installed system, repeat procedure volume, and net realized price.

Financial driver Near-term effect Longer-term effect
Device placement Increases hospital access Creates recurring procedure capacity
Surgeon training Slows early adoption Improves utilization and retention
Reimbursement Determines hospital economics Supports broader standard-of-care adoption
Clinical evidence Influences purchasing decisions Supports guideline and payer acceptance
Manufacturing scale Affects gross margin Can improve unit economics
International approvals Limited initial contribution Expands procedure base
New indications High development cost Could materially expand revenue

The initial financial profile is likely to include high commercial expenses. Lumicell must support capital equipment placement, field service, operating-room education, clinical evidence generation, regulatory compliance, and hospital contracting. Gross margin on the injectable product may improve with manufacturing scale, but early profitability can remain pressured by low utilization per installed system.

Is pegulicianine acetate generating disclosed revenue?

No public, audited product revenue figure has been disclosed in the principal public sources available for Lumicell. The company is privately held and does not provide the recurring quarterly financial reporting required of a publicly traded pharmaceutical company.

Publicly available information does not establish:

  • Net sales by quarter or year.
  • Product launch price.
  • Gross margin.
  • Number of installed Lumicell systems.
  • Number of Lumisight-treated procedures.
  • U.S. sales force size.
  • Commercial break-even date.
  • Cash runway.
  • Product-level operating expenses.
  • Royalty obligations or milestone payments.

The absence of disclosed revenue does not establish weak demand. It means the company’s financial trajectory cannot be measured through public income statements. Commercial diligence should therefore focus on hospital placements, utilization, reimbursement, procedure volumes, and evidence of re-excision reduction.

How does the competitive landscape compare with Lumisight?

Lumisight competes with existing surgical and pathology workflows rather than with one directly interchangeable drug.

Competitive approach Primary function Commercial advantage Limitation relative to Lumisight
Intraoperative pathology Margin assessment Established clinical practice Can add time and operating-room complexity
Postoperative pathology Definitive margin evaluation Required standard of care Results may require a second procedure
Specimen radiography Confirms excision of targeted lesions Widely used in breast surgery Does not directly provide fluorescence-based cavity imaging
Surgical judgment and visual inspection Immediate intraoperative assessment No added drug cost Limited sensitivity for occult residual disease
Lumisight plus Lumicell DVS Fluorescent cavity visualization Provides an additional intraoperative signal Requires drug, device, training, and workflow integration
Pafolacianine Fluorescent imaging in selected ovarian cancer surgery Validated fluorescent imaging platform in another indication Not a direct substitute for the breast-cancer indication

The strongest commercial argument is a potential reduction in positive margins and repeat operations. The strongest commercial barrier is that hospitals may view Lumisight as an incremental cost unless clinical and health-economic data show measurable savings or improved outcomes.

What generic entry risks exist for pegulicianine acetate?

Generic entry risk is lower than for a conventional oral small-molecule drug because Lumisight is used with a proprietary or specialized imaging system and requires procedure-level workflow adoption.

Potential entry routes include:

  • An ANDA for the drug product, if the product and device requirements can be adequately addressed.
  • A 505(b)(2) application relying partly on existing data.
  • A competing fluorescent imaging agent with a different mechanism.
  • A competing imaging device paired with a new agent.
  • Hospital-level substitution if a rival platform demonstrates equivalent clinical utility.

The device dependency raises practical barriers, but it does not eliminate pharmaceutical competition. A rival agent could target the same surgical problem without copying the exact molecular structure.

Paragraph IV challenges and patent litigation

No publicly established Paragraph IV challenge, FDA patent-certification dispute, or major patent litigation involving pegulicianine acetate is identified in the core public approval materials cited here. The product’s litigation exposure cannot be quantified from the FDA label alone.

The relevant legal protections are likely to include several layers:

  • Composition-of-matter patents covering the imaging agent.
  • Conjugate or linker patents.
  • Tumor-activated imaging chemistry.
  • Methods of detecting residual cancerous tissue.
  • Combination claims covering the agent and visualization system.
  • Manufacturing and formulation know-how.
  • Regulatory exclusivity associated with the approved product.

A competitor could attempt to design around composition claims while pursuing similar method-of-use claims. The commercial importance of device integration may therefore be comparable to the strength of the drug patent estate.

What patents protect pegulicianine acetate?

Public FDA materials do not provide a complete, authoritative list of all patent rights covering pegulicianine acetate, the Lumisight formulation, or the Lumicell imaging system. Patent protection should be assessed across the drug, device, use, and manufacturing layers rather than through a single patent number.

The most important diligence questions are:

Patent category Commercial relevance
Active-agent composition Can block direct chemical copies
Fluorophore and linker structure May protect design architecture
Tumor-activated mechanism Can limit competing use claims
Formulation and injectable stability Can delay practical substitution
Imaging-system integration Can restrict use of the approved workflow
Surgical method claims May cover intraoperative margin assessment
Manufacturing process Can increase cost and technical barriers for entrants

Orange Book status and exclusivity

The Orange Book position should be verified against the current FDA publication for the applicable NDA. Public approval documents establish FDA approval but do not, by themselves, establish the complete set of listed patents or the precise generic-entry date.

Pegulicianine is also not a biologic. Biosimilar competition is therefore not the relevant pathway. The principal regulatory risks are a generic or 505(b)(2) application, a competing imaging agent, and device-linked design-around strategies.

When does pegulicianine acetate lose exclusivity?

A definitive loss-of-exclusivity date cannot be calculated from the approval date alone. The date depends on:

  • The effective FDA approval date.
  • Whether the product received new chemical entity exclusivity.
  • Any patent term adjustment or patent term extension.
  • Listed patents and their expiration dates.
  • Pediatric exclusivity.
  • The legal pathway used by a challenger.
  • Litigation settlements or other agreements.

The FDA approval itself creates regulatory exclusivity only if the product qualifies under the relevant statutory category. A drug-device combination does not automatically produce a single exclusivity period that controls every component.

No publicly documented settlement agreement with a generic challenger is established in the cited sources. No biosimilar settlement is relevant because pegulicianine is a small-molecule imaging agent.

What licensing deals affect pegulicianine acetate?

Public FDA documents do not establish a complete licensing or royalty history for pegulicianine acetate. The commercial structure should be analyzed for rights to:

  • The active fluorophore.
  • Tumor-activated peptide or linker technology.
  • Manufacturing processes.
  • The Lumicell visualization system.
  • International commercialization.
  • Co-development or co-promotion.

An undisclosed royalty burden could reduce product gross margin even if procedure volumes grow. Conversely, an exclusive commercial partnership could accelerate hospital access while reducing Lumicell’s retained economics.

What generic launch scenarios are most likely?

Scenario 1: Controlled U.S. specialty launch

Lumicell places systems in selected breast centers and concentrates on high-volume surgeons. Revenue grows gradually, with early emphasis on evidence generation and hospital reference accounts. This is the most conservative commercial path.

Scenario 2: Evidence-led adoption

Clinical or health-economic results demonstrate fewer positive margins, fewer re-excisions, or lower total episode costs. Hospitals expand use across breast programs, increasing recurring Lumisight demand.

Scenario 3: Partnership-led expansion

A larger pharmaceutical, diagnostics, or surgical-device company provides distribution, capital, and international commercialization. This could improve scale but would likely reduce Lumicell’s share of economics.

Scenario 4: Competitive displacement

A rival imaging agent or device offers lower cost, easier workflow, stronger signal, or broader indications. Lumisight remains clinically differentiated but achieves limited utilization.

How strong is the commercial patent and market position?

Lumisight has a credible first-mover position in FDA-approved fluorescent margin visualization for breast-conserving surgery. Its commercial defensibility depends on more than molecular patents.

The strongest barriers are likely to be:

  • FDA approval for a defined surgical indication.
  • Integration of the drug with a specialized imaging device.
  • Surgeon and hospital workflow training.
  • Clinical evidence and institutional familiarity.
  • Manufacturing know-how.
  • Reimbursement and contracting infrastructure.

The main vulnerabilities are the narrow initial indication, absence of publicly disclosed revenue traction, dependence on hospital adoption, and possible competition from alternative imaging platforms.

Key Takeaways

  • Pegulicianine acetate is commercialized as Lumisight, an FDA-approved fluorescent imaging agent used with the Lumicell Direct Visualization System.
  • Its initial market is breast-conserving surgery, with revenue tied to procedure volume and hospital adoption.
  • The business model combines recurring drug sales with capital-equipment placement and service requirements.
  • Lumicell has not publicly disclosed product revenue, pricing, installed systems, or profitability.
  • Generic risk is moderated by device dependence and workflow integration, but competing imaging agents remain a material threat.
  • Biosimilar risk does not apply.
  • A definitive patent expiration or loss-of-exclusivity date cannot be established from the FDA label alone.
  • Commercial upside depends most heavily on evidence showing reduced re-excision rates, favorable health economics, and repeat use by high-volume breast centers.

FAQs

Is pegulicianine acetate the same product as Lumisight?

Yes. Lumisight is the commercial name for the pegulicianine fluorescent imaging product approved for use during breast-conserving surgery.

Is Lumisight a treatment for breast cancer?

No. Lumisight is an adjunctive imaging agent. It helps surgeons visualize tissue during surgery and does not treat breast cancer or replace histopathological analysis.

Can hospitals use Lumisight without the Lumicell imaging system?

The approved commercial workflow is designed for use with the Lumicell Direct Visualization System. The drug-device combination is central to the product’s regulatory and commercial model.

Does pegulicianine acetate have biosimilar competition?

No. Pegulicianine is a small-molecule imaging agent, so biosimilar regulations do not apply. Potential competition would more likely come from generic, 505(b)(2), or alternative fluorescent imaging products.

What evidence would most improve the Lumisight financial outlook?

Evidence of lower positive-margin rates, fewer repeat breast surgeries, favorable hospital economics, strong per-system utilization, and broad payer support would provide the clearest basis for a higher commercial forecast.

References

  1. U.S. Food and Drug Administration. (2024). Lumisight (pegulicianine) injection prescribing information.
  2. U.S. Food and Drug Administration. (2024). FDA approves imaging drug and device to help identify cancerous tissue during breast cancer surgery.
  3. ClinicalTrials.gov. (2024). Study of pegulicianine fluorescence imaging in breast-conserving surgery. National Library of Medicine.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.